Viread Approved for Hepatitis B

Illnesses & Conditions Drug Guide FDA Drug Approvals Medical Tests
Self-Help Resources Complementary Medicine Medline Search Informacion de Salud Referencia de Medicamentos

Allergies    Asthma    Back Pain    Cancer    Caregiver    Depression    Diabetes
Digestive Disorders    Heart Disease    Kidney Disease
Men's Health    Pregnancy    Senior's Health    Stress    Stroke    Women's Health

Fitness Nutrition Mind & Body Family & Home

Health News
Daily articles from HealthDay News: breaking news on health issues, drug approvals and recent discoveries.

Viread Approved for Hepatitis B

Already sanctioned to treat HIV

TUESDAY, Aug. 12 (HealthDay News) -- Viread (tenofovir disoproxil fumarate) has been approved by the U.S. Food and Drug Administration to treat chronic hepatitis B infection in adults.

The Gilead Sciences drug has been approved since 2001 to treat HIV/AIDS.

A serious liver disease, chronic hepatitis B affects about 400 million people globally and some 2 million in the United States, the manufacturer said in a news release. Asian Americans account for nearly half of all cases of the infection, which is a leading cause of liver cancer.

A once-daily tablet, Viread blocks an enzyme called HBV DNA polymerase, which is needed by the hepatitis B virus to replicate in liver cells.

More information

The FDA has more about this drug's approval history.

Health News Provided By:
HealthDay